We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Probiotec Limited is a drug manufacturers-specialty & generic business based in Australia. Probiotec shares (PBP) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Probiotec has a trailing 12-month revenue of around $120.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $1.8887 - $2.4436 |
|---|---|
| 50-day moving average | $2.162 |
| 200-day moving average | $2.134 |
| Target price | $2.9 |
| PE ratio | 36.3934 |
| Dividend yield | $0.05 (2.29%) |
| Earnings per share (TTM) | $0.061 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.22
| 1 week (2021-11-25) | 1.83% |
|---|---|
| 1 month (2021-11-05) | 4.72% |
| 3 months (2021-09-03) | 0.91% |
| 6 months (2021-06-04) | 13.27% |
| 1 year (2020-12-04) | -6.72% |
|---|---|
| 2 years (2019-12-05) | 18.09% |
| 3 years (2018-12-05) | 50.00% |
| 5 years (2016-12-05) | 404.55% |
Valuing Probiotec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Probiotec 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Probiotec 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Probiotec shares trade at around 36x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Probiotec 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.5 million (£0.0 million).
The EBITDA is a measure of a Probiotec 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $120.5 million |
|---|---|
| Operating margin TTM | 9.15% |
| Gross profit TTM | $38.7 million |
| Return on assets TTM | 3.78% |
| Return on equity TTM | 7.85% |
| Profit margin | 4.02% |
| Book value | 0.874 |
| Market capitalisation | $167.9 million |
TTM: trailing 12 months
Dividend payout ratio: 71.43% of net profits
Recently Probiotec has paid out, on average, around 71.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Probiotec shareholders could enjoy a 2.25% return on their shares, in the form of dividend payments. In Probiotec 's case, that would currently equate to about A$0.05 per share.
Probiotec 's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Over the last 12 months, Probiotec 's shares have ranged in value from as little as $1.8887 up to $2.4436. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Probiotec 's is 0.4791. This would suggest that Probiotec 's shares are less volatile than average (for this exchange).
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, ointments, and suspensions; powders and powder blending; and sprays, as well as manufactures and packages finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. In addition, the company provides packing services pharmaceutical, consumer, healthcare, cosmetics, and food and beverage companies. Probiotec Limited was incorporated in 1996 and is headquartered in Laverton North, Australia.
Everything we know about the Allup Silica IPO, plus information on how to buy in.
From where the no-makeup makeup look meets the model off duty vibe, we've put together a range of no-fuss products you'll love.
Every man wanted her – 1 man dared to love her.
Manchester United are scrambling to stay in touch with the top 4 as they host Arsenal this week
From toys to socks to beauty items, these are the top 12-day advent calendars you can still enjoy in the lead up to Christmas.
Steps to owning and managing McDonald's shares from in Australia.
Reputation + Christmas parties: could it be the potential volcano erupting leaving rands, families and individuals to deal with the fallout?
Insurtech Flip has shaken up the insurance industry by launching the first on-demand injury cover in the country.
Everything we know about the Qualitas Limited IPO, plus information on how to buy in.
